1. Home
  2. EVO

EVO

Evotec SE

Logo Evotec SE

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The EVT Execute segment, about 75% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment, about 25% of sales, develops proprietary drug discovery programs and assets, which can lead to partnerships with clients. As of 2022, the company has almost 5,000 employees and 17 production sites mainly in Europe and the United States.

Founded: 1993 Country:
Germany
Germany
Employees: 5086 City: N/A
Market Cap: 2.5B IPO Year: 2021
Target Price: $14.33 AVG Volume (30 days): 56.1K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.28 EPS Growth: N/A
52 Week Low/High: $6.83 - $13.49 Next Earning Date: 05-10-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 4.86% Revenue Growth (next year): 18.14%

Share on Social Networks: